Dermata Therapeutics DRMA Income Statement (2020-2026)

NASDAQ DRMA
$1.38 -0.09 (-6.12%)
At close: Aug 20, 2026 · 4:00 PM EDT
Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Shares Outstanding (Entity) (Quarter)
796.000.00M0.00M0.00M0.00M0.01M0.01M0.01M0.02M0.02M0.02M0.04M0.07M0.17M0.15M0.52M1.03M0.84M0.93M4.02M
Operating items
Research & Development (Quarter)
0.87M0.80M1.11M1.60M1.61M1.55M0.89M1.19M0.84M0.90M1.14M1.60M2.01M2.40M2.19M7.00M0.62M0.50M0.53M0.38M
Selling, General & Administrative (Quarter)
0.46M0.91M1.44M1.19M1.12M0.89M0.82M1.09M0.89M0.91M1.08M1.60M0.87M0.82M1.01M1.06M1.15M1.26M1.37M1.54M
Restructuring Costs (Quarter)
0.03M1.24M0.16M0.21M0.18M0.17M0.08M0.08M0.08M0.08M0.35M0.01M0.02M0.03M
Other Operating Expenses (Quarter)
-0.03M-1.24M-0.16M-0.21M-0.18M-0.17M-0.08M-0.08M-0.08M-0.08M-0.35M-0.01M-0.02M-0.03M-5.72M
Operating Expenses (Quarter)
1.33M1.71M2.55M2.79M2.73M2.45M1.71M2.28M1.73M1.81M2.22M3.20M2.88M3.23M3.20M2.34M1.77M1.76M1.90M1.93M
Operating Income (Quarter)
-1.33M-1.71M-2.55M-2.79M-2.73M-2.45M-1.71M-2.28M-1.73M-1.81M-2.22M-3.20M-2.88M-3.23M-3.20M-2.34M-1.77M-1.76M-1.90M-1.93M
EBIT (Quarter)
-1.33M-1.71M-2.55M-2.79M-2.73M-2.45M-1.71M-2.28M-1.73M-1.81M-2.22M-3.20M-2.88M-3.23M-3.20M-2.34M-1.77M-1.76M-1.90M-1.93M
Non-operating items
Interest & Investment Income (Quarter)
0.04M0.03M0.09M0.09M0.07M0.05M0.05M0.05M0.04M0.07M0.07M0.04M0.08M
Other Non Operating Income (Quarter)
1.33M
Net income details
EBT (Quarter)
-1.33M-4.28M-2.55M-2.99M-2.73M-2.42M-1.71M-2.24M-1.70M-1.72M-2.26M-4.03M-4.43M-4.97M-4.45M-3.00M-1.70M-1.69M-1.86M-1.85M
Profit After Tax (Quarter)
-1.33M-1.71M-2.55M-2.79M-2.73M-2.42M-1.67M-2.24M-1.70M-1.72M-2.13M-3.13M-2.83M-3.17M-3.15M-2.30M-1.70M-1.69M-1.86M-1.85M
Income from Continuing Operations (Quarter)
-1.33M-4.28M-2.55M-2.99M-2.73M-2.42M-1.71M-2.24M-1.70M-1.72M-2.26M-4.03M-4.43M-4.97M-4.45M-3.00M-1.70M-1.69M-1.86M-1.85M
Consolidated Net Income (Quarter)
-1.33M-4.28M-2.55M-2.99M-2.73M-2.42M-1.71M-2.24M-1.70M-1.72M-2.26M-4.03M-4.43M-4.97M-4.45M-3.00M-1.70M-1.69M-1.86M-1.85M
Income towards Parent Company (Quarter)
-1.33M-4.28M-2.55M-2.99M-2.73M-2.42M-1.71M-2.24M-1.70M-1.72M-2.26M-4.03M-4.43M-4.97M-4.45M-3.00M-1.70M-1.69M-1.86M-1.85M
Preferred Dividend Payments (Quarter)
2.29M
Net Income towards Common Stockholders (Quarter)
-1.33M-4.28M-2.55M-2.99M-2.73M-2.42M-1.71M-2.24M-1.70M-1.72M-2.26M-4.03M-4.43M-4.97M-4.45M-3.00M-1.70M-1.69M-1.86M-1.85M
Additional items
EPS (Basic) (Quarter)
-0.00M-0.00M-0.00M-858.09-585.33-474.01-371.70-340.81-94.35-80.86-116.07-90.85-65.46-31.99-29.10-5.83-1.66-1.65-2.01-0.48
EPS (Diluted) (Quarter)
-116.09-90.86-65.47-31.99-29.10-5.83-1.66-1.65-2.01-0.48
Shares Outstanding (Quarter)
796.000.00M0.00M0.00M0.00M0.01M0.00M0.01M0.02M0.02M0.02M0.04M0.07M0.16M0.15M0.52M1.03M1.03M0.93M3.86M
Shares Outstanding (Diluted) (Quarter)
0.02M0.04M0.07M0.16M0.15M0.52M1.03M1.03M0.93M3.86M
EBITDA (Quarter)
-1.33M-1.71M-2.55M-2.79M-2.73M-2.45M-1.71M-2.28M-1.73M-1.81M-2.22M-3.20M-2.88M-3.23M-3.20M-2.34M-1.77M-1.76M-1.90M-1.93M
Interest Expenses (Quarter)
0.00M651.000.20M0.13M0.90M1.60M1.80M1.30M0.70M